To compare and analyze the therapeutic effect of tumor-derived heat shock protein 70 and globally accepted interleukin-2, to evaluate the anti-tumor capacity of HSP70, and to provide significant information for HSP70 administration to treat human cancers.
Cell Culture, techniques for protein extraction and purification, SDS-PAGE, Western-blot and animal experiment were used in this study.
Both IL-2 and HSP70 showed therapeutic effect in tumor-bearing mice. The best effect was observed in 100 000 U IL-2 and 10 μg HSP70 administrations, and partial efficacy was found in 50000 U IL-2 and 5 μg HSP70 administrations. The effect of 100000 U IL-2 was nearly as good as that of 5 μg HSP70. About 40 % mice receiving HSP70 10 μg administration survived over 90 days, the average survival period of this group was over 56.8 days, whereas the control group was 17.3 days, IL-2 50 000 group, 26.3 days, IL-2 100 000 group, 36.6 days, and 5 μg HSP70 group, 27.7 days. Significant difference was found (P<0.05) when compared with the HSP70 10 μg group and control group.
HSP70 has a specific anti-tumor effect and obviously exceeded IL-2 .Those data provide significant information for the treatment of human cancers.